CA2550155C - Hla-dr-specific antibodies, compositions and methods - Google Patents

Hla-dr-specific antibodies, compositions and methods Download PDF

Info

Publication number
CA2550155C
CA2550155C CA2550155A CA2550155A CA2550155C CA 2550155 C CA2550155 C CA 2550155C CA 2550155 A CA2550155 A CA 2550155A CA 2550155 A CA2550155 A CA 2550155A CA 2550155 C CA2550155 C CA 2550155C
Authority
CA
Canada
Prior art keywords
ser
hla
seq
thr
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2550155A
Other languages
English (en)
French (fr)
Other versions
CA2550155A1 (en
Inventor
Catherine J. Mcmahan
Lara Porter Stepan
Reiner Laus
Damir Vidovic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dendreon Pharmaceuticals LLC
Original Assignee
Dendreon Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dendreon Corp filed Critical Dendreon Corp
Publication of CA2550155A1 publication Critical patent/CA2550155A1/en
Application granted granted Critical
Publication of CA2550155C publication Critical patent/CA2550155C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2550155A 2003-12-15 2004-12-15 Hla-dr-specific antibodies, compositions and methods Expired - Fee Related CA2550155C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60894403P 2003-12-15 2003-12-15
US60/608,944 2003-12-15
PCT/US2004/042312 WO2005058251A2 (en) 2003-12-15 2004-12-15 Hla-dr-specific antibodies, compositions and methods

Publications (2)

Publication Number Publication Date
CA2550155A1 CA2550155A1 (en) 2005-06-30
CA2550155C true CA2550155C (en) 2015-03-17

Family

ID=34700255

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2550155A Expired - Fee Related CA2550155C (en) 2003-12-15 2004-12-15 Hla-dr-specific antibodies, compositions and methods

Country Status (5)

Country Link
US (1) US8354507B2 (enExample)
EP (1) EP1711527A4 (enExample)
JP (1) JP2007513976A (enExample)
CA (1) CA2550155C (enExample)
WO (1) WO2005058251A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2625222A1 (en) * 2005-10-11 2007-04-19 Domantis Limited Antibody polypeptide library screening and selected antibody polypeptides
GB0525214D0 (en) * 2005-12-12 2006-01-18 Bioinvent Int Ab Biological materials and uses thereof
US9085614B2 (en) * 2008-08-01 2015-07-21 Immunas Pharma, Inc. Antibodies that specifically bind to Aβ oligomers and uses thereof
WO2011156328A1 (en) * 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
KR102096224B1 (ko) 2011-10-28 2020-04-03 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 폴리펩티드 구축물 및 이의 용도
KR20150132581A (ko) * 2013-12-31 2015-11-25 재단법인 생물기술개발중심 항-vegf 항체 및 그것의 용도
AU2016270474A1 (en) * 2015-06-04 2018-01-04 University Of Southern California Lym-1 and Lym-2 targeted CAR cell immunotherapy
BR112018012344A2 (pt) * 2015-12-17 2018-12-04 Janssen Biotech Inc anticorpos que se ligam especificamente a hla-dr e seus usos
JP7224289B2 (ja) 2016-09-21 2023-02-17 アプティーボ リサーチ アンド デベロップメント エルエルシー Cd123結合タンパク質並びに関連する組成物及び方法
JP2020501512A (ja) * 2016-09-23 2020-01-23 ユニバーシティ オブ サザン カリフォルニア キメラ抗原受容体およびその組成物ならびにそれらの使用の方法
KR102869563B1 (ko) 2017-07-17 2025-10-10 얀센 바이오테크 인코포레이티드 피브로넥틴 iii형 도메인에 대한 항원 결합 영역 및 이의 사용 방법
JP2022520106A (ja) 2019-02-15 2022-03-28 ユニバーシティ オブ サザン カリフォルニア Lym-1およびlym-2抗体組成物ならびに改善されたcar構築物
WO2020204054A1 (en) * 2019-04-01 2020-10-08 Chugai Seiyaku Kabushiki Kaisha Anti-hla-dq2.5 antibody
CN115028730B (zh) * 2022-05-17 2022-11-08 诺赛联合(北京)生物医学科技有限公司 一种成体干细胞衍生的类器官制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0698021B2 (ja) 1986-08-01 1994-12-07 帝人株式会社 マウス−ヒトキメラ抗体、それをコ−ドする発現型キメラdna配列、プラスミド及び細胞
NO873164L (no) 1986-07-30 1988-02-01 Teijin Ltd Muse-humane kimaere antistoffer.
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
PT877626E (pt) 1996-01-23 2003-01-31 Univ Vermont And State Agric C Anticorpos anti-cd1s para utilizacao contra icto
JP4481489B2 (ja) * 1998-01-23 2010-06-16 エフ.ホフマン−ラ ロシュ アーゲー ヒトil−12に対する抗体
WO2000012560A1 (en) * 1998-08-28 2000-03-09 Dendreon Corporation Selective apoptosis of neoplastic cells by an hla-dr specific monoclonal antibody
CA2362592A1 (en) * 1999-02-12 2000-08-17 Genetics Institute, Inc. Humanized immunoglobulin reactive with b7 molecules and methods of treatment therewith
EP1156060B1 (en) 2000-05-12 2007-06-27 GPC Biotech AG Human peptides/proteins causing or leading to the killing of cells including lymphoid tumor cells
KR20050036852A (ko) * 2001-10-15 2005-04-20 기린 비루 가부시키가이샤 항-hla-dr 항체
PT1461428E (pt) * 2001-12-03 2012-05-29 Alexion Pharma Inc Método para produção de anticorpos híbridos
US8450348B2 (en) * 2007-02-21 2013-05-28 Forma Tm, Llc Derivatives of squaric acid with anti-proliferative activity

Also Published As

Publication number Publication date
JP2007513976A (ja) 2007-05-31
US20050208048A1 (en) 2005-09-22
EP1711527A4 (en) 2008-09-03
WO2005058251A3 (en) 2005-11-17
WO2005058251A2 (en) 2005-06-30
EP1711527A2 (en) 2006-10-18
US8354507B2 (en) 2013-01-15
CA2550155A1 (en) 2005-06-30

Similar Documents

Publication Publication Date Title
CN103687945B (zh) 抗-b7-h3抗体
DK2740744T3 (da) Sp35-antistoffer og anvendelser deraf
EP2516468B1 (en) Anti-flt3 antibodies and methods of using the same
JP6205363B2 (ja) ハイブリッド定常領域
JP6097690B2 (ja) 抗cxcl13抗体およびそれを用いる方法
US8007798B2 (en) Treatment of complement-associated disorders
CA2550155C (en) Hla-dr-specific antibodies, compositions and methods
DK2644205T3 (en) Targeting ABCB5 for Cancer Therapy
US7115713B2 (en) Compounds, compositions and methods for the treatment of diseases characterized by A-33 related antigens
KR20020026542A (ko) 부자극 신호 전달 분자 에이아이엘아이엠에 대한 인간모노클로날 항체 및 그의 약학적 용도
CA2689680A1 (en) Fc receptor-binding polypeptides with modified effector functions
US7192589B2 (en) Treatment of inflammatory disorders with STIgMA immunoadhesins
KR102862077B1 (ko) 인간화 항-n-절단 아밀로이드 베타 단일 클론 항체
TW201942135A (zh) 抗cd27 抗體、其抗原結合片段及其醫藥用途
JP2015518857A (ja) Il−6結合分子
JPH10257893A (ja) ガングリオシドgm2に対するヒト型相補性決定領域(cdr)移植抗体
US11542322B2 (en) Nano-theranostics for Parkinson's disease
JP2005519590A (ja) 免疫関連疾患の治療のための組成物及び方法
JP2024535124A (ja) 破傷風毒素に結合する抗体およびその使用
KR20240047964A (ko) 항-csp 항체
JP2003524600A (ja) 免疫関連疾患治療のための組成物及び方法
US10870694B2 (en) Composition and methods of treating B cell disorders
AU778551B2 (en) Novel peptide and screening method by using the same
US7198917B2 (en) Compounds, compositions and methods for the treatment of diseases characterized by A-33 related antigens
JP2023504974A (ja) 抗tirc7抗原結合タンパク質

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20181217